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A Case of Multicentric Castleman’s Disease Having Lung Lesion 
Successfully Treated with Humanized Anti-interleukin-6 Receptor 
Antibody, Tocilizumab
This report presents the case of a patient demonstrating multicentric Castleman’s disease 
(MCD) with a lung lesion that was successfully treated with an anti-interleukin-6 receptor 
antibody, tocilizumab in combination with corticosteroid and tacrolimus. A 43-yr-old 
female with abnormal shadows on a chest X-ray was referred to the hospital for further 
examination. She was diagnosed as having MCD based on the characteristic pathology of 
inguinal lymph node, lung lesions, laboratory data, and undifferentiated arthritis. 
Corticosteroid and rituximab therapy did not fully ameliorate the symptoms; thus, the 
therapeutic regimen was changed to include tocilizumab, oral corticosteroid and tacrolimus. 
This regimen resulted in clinical remission and the dose of tocilizumab and corticosteroid 
could be tapered. Tocilizumab in combination with corticosteroid and tacrolimus may 
therefore be a beneficial treatment regimen for lung lesions associated with MCD.
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CASE REPORT
Immunology, Allergic Disorders & Rheumatology
INTRODUCTION
Castleman’s disease is a lymphoproliferative disorder with be-
nign hyperplastic lymph nodes characterized histologically by 
(A) follicular hyperplasia, and (B) capillary proliferation with 
endothelial hyperplasia (1). This disease has been classified his-
topathologically as hyalinevascular, plasma cell, or a mixed type 
variant of the two (2, 3). The plasma cell and mixed types are  
often associated with ‘multicentric Castleman’s disease’ (MCD), 
which shows various systemic manifestations, such as fever, ane-
mia, hypergammaglobulinemia, hypoalbuminemia, and an in-
crease in acute phase proteins (2). MCD is often refractory to 
conventional therapeutic strategies, such as corticosteroid, cy-
totoxic agents, and/or radiation (4, 5). The frequency of MCD 
associated with a lung lesion among the Japanese population is 
high (~70%) (6) and such progressive lung lesions often lead to 
death (2, 7). 
  Interleukin-6 (IL-6) is a pleiotropic cytokine with a wide range 
of biologic activities, such as hematopoiesis, regulation of im-
mune responses, and inflammatory responses (4). Patients with 
the plasma cell type Castleman’s disease often generate large 
quantities of IL-6 in the germinal centers of hyperplastic lymph 
nodes (8). 
  ‘Tocilizumab’ is a  humanized anti-interleukin-6 receptor an-
tibody that neutralizes the pleiotropic actions of IL-6. It was ap-
proved for use in Japan for the treatment of Castleman’s disease 
in 2005.
  This report describes a case of MCD with an associated lung 
lesion, which responded dramatically to tocilizumab in combi-
nation with corticosteroid and tacrolimus.
CASE REPORT
A 43-yr-old female visited a nearby hospital because of abnor-
mal shadows including multiple nodules and reticular shadows 
on chest radiography found at an annual medical checkup in 
2005. A bronchoscopic examination was performed. They were 
unable to obtain a biopsy specimen from one of the nodules in 
S10 of the left lung because the patient had a strong bleeding 
tendency. She was referred to this hospital for further examina-
tion on June 30, 2005. 
  On admission, her height was 157.5 cm and weight, 50.3 kg. 
Her consciousness was clear. The conjunctivas were anemic and 
not jaundiced. Her heart sounds were normal. Fine crackles were 
audible in the right lower lung field. The abdomen was not dis-
tended. Her inguinal lymph nodes were palpable and no other 
superficial lymph nodes were palpable. She was experiencing 
slight polyarthralgia, however, radiography films showed no joint Higuchi T, et al.  •  MCD Having Lung Lesion 
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anomalies. 
  The laboratory data were: erythrocyte sedimentation rate, 119 
mm/1 hr; white cell count, 8,900/μL; hemoglobin, 8.4 g/dL; plate-
let count, 39.4×10
4/μL; serum aspartate aminotransferase, 22 IU/ 
L; alanine aminotransferase, 22; total protein, 9.7 g/dL; albumin 
2.6; creatinine, 0.48; PT, 13.1 sec (INR 1.45); aPTT, 39.6 (control, 
10.4); fibrinogen, 750 mg/dL; KL-6, 277 U/mL (reference range 
<500); C-reactive protein, 11.7 mg/dL (<0.3); serum immuno-
globulin (Ig)G, 4,570 (870-1740); IgA, 491(110-400), IgM, 706 (35-
220), CH50, 52.3 U/mL (30-50), soluble IL-2 receptor, 1,400; se-
rum IL-6, 6.8 pg/mL (<4); rheumatoid factor (RF), 1,330 IU/mL 
(<20). Autoantibodies, including antinuclear antibody, anti-ds-
DNA, anti-Sm, anti-RNP, cytoplasmic antineutrophil cytoplas-
mic antibody (ANCA), and myeloperoxidase-ANCA were all 
negative. M-protein was not noted in serum immunoelectro-
phoresis. Bone marrow aspiration showed hyperplasia with no 
abnormal morphology on smear specimens. 
  Chest radiographys showed multiple nodules and reticular 
shadows mainly in the lower lung field. Chest CT scan disclosed 
a slight enlargement of the mediastinal lymph nodes, centrilob-
ular nodules, thin-walled cysts, the thickening of the broncho-
vascular bundles, and ground-grass opacities, all of these find-
ings were compatible with those of lymphocytic interstitial pneu-
monia (LIP; Fig. 1A) (5, 9). 
67Gallium citrate scintigraphy did not 
reveal any evident accumulation. 
  A lung surgeon and a thoracic physician declined to perform 
a lung biopsy because of her bleeding tendency (bleeding time: 
6 min 30 sec) and poor general condition. A biopsy of an ingui-
nal lymph node was obtained for making a definite diagnosis 
(Fig. 2). She was diagnosed with MCD and undifferentiated ar-
thritis based on the characteristic pathology of the specimen of 
the inguinal lymph node, CT findings of the bilateral lung lesions 
and laboratory data.
  She was initially administered intravenous corticosteroid 
(methylprednisolone, 500 mg/day, 3 consecutive days) follow-
ed by oral corticosteroid (methylprednisolone, 16 mg/day), and, 
375 mg/m
2 rituximab every week for 4 weeks. The polyarthralgia 
instantly disappeared; however, none of the other clinical and 
laboratory parameters were fully resolved. Therefore the thera-
peutic regimen was changed to tocilizumab (8 mg/kg, every 2 
weeks), oral corticosteroid (methylprednisolone, 16 mg/day) on 
October 25, 2005. The patient requested that the interval between 
tocilizumab to be increased to more than every two weeks. The 
dose of corticosteroid in combination with tocilizumab should 
Fig. 1. Chest CT findings (A) just before the second regimen, of tocilizumab in combination with corticosteroid and tacrolimus: centrilobular nodules, thin walled cysts, the 
thickening of the bronchovascular bundles and ground-grass opacities were noted; (B) Thirteen months after the continuation of the second regimen; (C) after twenty three 
months: most of the lesions had alleviated.
A B C
Fig. 2. The specimen obtained from the inguinal lymph node. Microscopic exami  nation of the lymph node showed typi  cal features of plasma cell type Castleman’s disease (A, 
H&E stain, ×40; B, H&E stain, ×200).
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be kept as low as possible to avoid various side effects, such as 
osteoporosis, hyperglycemia, and hypertension. It is indicated 
for the treatment of rheumatoid arthritis in Japan. The addition 
of tacrolimus to the regimen was considered to fulfill such re-
quirements. Both the possible merits and demerits of the drug 
were explained to the patient and her oral consent was obtained. 
Tacrolimus (3 mg/day) was introduced on November 10, 2005. 
Laboratory findings, including anemia, hypergammaglobu-
linemia, and an increase in acute phase proteins responded to 
this regimen (Fig. 3). The enlargement of mediastinal lymph 
nodes and abnormal shadows were also partially alleviated 
(Fig. 1B, C). The intervals of the tocilizumab-administration 
sessions were extended from every 2 weeks to every 3 weeks 
from January 2006. Oral corticosteroid was gradually tapered 
from 16 mg/day finally to 4 mg/day. The dose of tacrolimus has 
been unchanged. The disease activity has been totally suppress-
ed for 36 months by this maintenance regimen.
DISCUSSION
The treatment of MCD includes various therapeutic strategies 
such as corticosteroid, chemotherapy, rituximab, or tocilizumab. 
Rituximab, an immunoglobulin G1 (IgG1) κ monoclonal anti-
body to CD20, has the potential for B-lymphocyte depletion via 
antibody-dependent cell mediated-cytotoxicity (ADCC), com-
plement dependent cytotoxicity (CDC), and apoptosis. Kaposi’s 
sarcoma-associated herpes virus (KSHV/HHV8) was thought 
to be associated with the development of Castleman’s disease, 
especially in patients infected with human immunodeficiency 
virus (HIV) and rituximab was reported to be effective in HIV-
related Castleman’s disease (11). The effectiveness of rituximab 
was limited in the present case because the patient was not in-
fected with HIV. A humanized anti-interleukin-6 receptor anti-
body, tocilizumab, was shown to be effective for the treatment 
of MCD in an open label trial, and has been widely used in Ja-
pan (5).
  The frequency of MCD associated with a lung lesion is rela-
tively low (10-20%) in the United States. In contrast, Nishimoto 
et al. reported that 18 of 28 Japanese cases (=64.3%) had a lung 
lesion (6). The CT findings of intrathoracic involvement in MCD 
include bilateral hilar and mediastinal lymphadenopathy, cen-
trilobular nodular opacities, thin-walled cysts, interlobular sep-
tal thickening, and ground-glass attenuation (9). Some reports 
have noted that the lung lesion in MCD is compatible with lym-
phocytic interstitial pneumonia (LIP) (5, 9). 
  Ohno et al. (12) reported a case of MCD with a lung lesion 
that responded to tocilizumab. In contrast, Akahane et al. (7)
describ  ed that the administration of tocilizumab for 2 yr had no 
effect on the lung lesion in an MCD patient. The main target of 
calcineurin inhibitors is generally thought to be T cells. IL-6 pro-
duction by the germinal center B cells in the swollen lymph 
nodes of patients with MCD is remarkable (8), but the roles of T 
cells are unknown. If T cells do participate in the pathogenesis, 
immunosuppressive drugs for T cells should be useful. In fact, 
MCD, which is classified as a lymphoproliferative disorder, has 
characteristics of an autoimmune disease, demonstrated by the 
production of autoantibodies. Several studies have shown that 
these drugs are active not only against T cells but also against 
other cells. For example, they are used for the treatment of RA. 
They suppress the promotion of IL-6 in the rheumatoid synovi-
um where T cells are relatively scarce (13). They also suppress 
IL-6 production in monocytes, and TNF-α production in B cells 
(14, 15). Pham et al. (16) reported that inhibition of NF-κB and 
NFAT activation in aggressive B-cell lymphomas by calcineurin 
inhibitors suppressed the CD40 ligand expression in B cells and 
lymphoma cell survival in an in vitro experiment. Some of these 
actions of tacrolimus, if not all, may be associated with the effi-
cacy of the drug for the treatment of MCD. In fact, Miltenyi et al. 
(17) reported that non-cytostatic immunomodulatory therapy 
including corticosteroid, cyclosporine A and thalidomide treat-
ment was effective for Castleman’s disease.
  The long-time use of tocilizumab and corticosteroid is neces-
sary for the treatment of MCD. Corticosteroid has various dose-
related side effects, and acquisition of drug resistance possible. 
P-glycoprotein (P-gp) plays a pivotal role in the latter. Peripher-
al lymphocytes in patients with autoimmune diseases could 
express P-gp on their cell surface. Calcineurin inhibitors have 
an antagonistic activity to P-gp: they may inhibit corticosteroid-
Fig. 3. Clinical course of the patient. 
mPSL, methylprednisolone; RTX, rituximab 375 mg/m
2; tocilizumab,tocilizumab 6 mg/ 
kg. The dose of mPSL could be gradually tapered from 16 mg/day to 4 mg/day. 
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resistance in peripheral lymphocytes in vivo (18, 19). The dose 
of corticosteroid could be tapered in the current case, at least in 
part, due to the antagonistic activity to P-gp of tacrolimus. 
  In conclusion, this is the first report to describe that tocilizum-
ab, in combination with corticosteroid and tacrolimus, shows a 
dramatic effectiveness in the treatment of a lung lesion in an 
MCD patient. 
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